Showing results (11-20 of 113) with videos related to
Sort By:
Pageof 12
Clinical Calcium|November 27, 2015
[IL-6 inhibitors prevent bone loss and cartilage degeneration in rheumatoid arthritis]Miho Murakami, Norihiro NishimotoEndocrine, Metabolic & Immune Disorders Drug Targets|January 12, 2007
Anti-interleukin-6 receptor antibody therapy in rheumatic diseasesHideko Nakahara, Norihiro NishimotoExpert Review of Clinical Immunology|May 19, 2010
Tocilizumab for the treatment of rheumatoid arthritisToru Mima, Norihiro NishimotoPDA Journal of Pharmaceutical Science and Technology|December 18, 2003
Determination of conditions for the production scale sterilization of prefilled syringesNorihiro Nishimoto, Tatsuyuki MaekawaModern Rheumatology|July 10, 2010
Assessment of the validity of the 28-joint disease activity score using erythrocyte sedimentation rate (DAS28-ESR) as a disease activity index of rheumatoid arthritis in the efficacy evaluation of 24-week treatment with tocilizumab: subanalysis of the SATORI studyNorihiro Nishimoto, Nobuhiro TakagiCurrent Opinion in Pharmacology|July 15, 2004
Inhibition of IL-6 for the treatment of inflammatory diseasesNorihiro Nishimoto, Tadamitsu KishimotoCurrent Opinion in Rheumatology|April 15, 2009
Clinical value of blocking IL-6 receptorToru Mima, Norihiro NishimotoCurrent Opinion in Rheumatology|March 24, 2011
The value of blocking IL-6 outside of rheumatoid arthritis: current perspectiveMiho Murakami, Norihiro NishimotoClinical Calcium|October 30, 2012
[Inflammatory cytokines in rheumatoid arthritis]Miho Murakami, Norihiro NishimotoNihon Rinsho. Japanese Journal of Clinical Medicine|January 4, 2003
[A humanized anti-IL-6 receptor antibody(MRA) in RA therapy]Keisuke Hagihara, Norihiro Nishimoto, Kazuyuki YoshizakiPageof 12